Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. Catapres
2. Catapresan
3. Catapressan
4. Chlophazolin
5. Clofelin
6. Clofenil
7. Clonidine
8. Clonidine Dihydrochloride
9. Clonidine Monohydrobromide
10. Clonidine Monohydrochloride
11. Clopheline
12. Dihydrochloride, Clonidine
13. Dixarit
14. Gemiton
15. Hemiton
16. Hydrochloride, Clonidine
17. Isoglaucon
18. Klofelin
19. Klofenil
20. M 5041t
21. M-5041t
22. M5041t
23. Monohydrobromide, Clonidine
24. Monohydrochloride, Clonidine
25. St 155
26. St-155
27. St155
1. 4205-91-8
2. Clonidine Hcl
3. 2-(2,6-dichloroanilino)-2-imidazoline Hydrochloride
4. Kapvay
5. N-(2,6-dichlorophenyl)-4,5-dihydro-1h-imidazol-2-amine Hydrochloride
6. St-155
7. Catapresan
8. Jenloga
9. Clonidine (hydrochloride)
10. Nsc-756699
11. 2-(2,6-dichlorophenylamino)-2-imidazoline Hydrochloride
12. W76i6xxf06
13. Dichloranilino Imidazolin
14. 2-((2,6-dichlorophenyl)imino)imidazolidine Monohydrochloride
15. Benzenamine, 2,6-dichloro-n-2-imidazolidinylidene-, Monohydrochloride
16. Chlophazolin
17. Dispaclonidin
18. Normopresan
19. Atensina
20. Barclyd
21. Capresin
22. Caprysin
23. Catanidin
24. Clofelin
25. Clonilou
26. Clonisin
27. Clonistada
28. Dixarit
29. Edolglau
30. Glausine
31. Haemiton
32. Ipotensium
33. Isoglaucon
34. Katapresan
35. Klophelin
36. Iporel
37. 1h-imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- [cas]
38. Apo-clonidine
39. Clonidil-riker
40. Novo-clonidine
41. Clonid-ophal
42. Nu-clonidine
43. N-(2,6-dichlorophenyl)-4,5-dihydro-1h-imidazol-2-amine Hcl
44. 1h-imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-, Monohydrochloride (9ci)
45. 2-[(2,6-dichlorophenyl)amino-2-imidazoline Hydrochloride
46. Bapresan
47. Clonicel
48. Trialox
49. Clonidine Monohydrochloride
50. Smr000466276
51. 205c918
52. Sr-01000075246
53. Einecs 224-121-5
54. Cas-4205-91-8
55. Mfcd00036705
56. N-(2,6-dichlorophenyl)imidazolidin-2-imine;hydrochloride
57. Unii-w76i6xxf06
58. Clonidine-hcl
59. Sr-01000759380
60. Prestwick_73
61. Catapres (tn)
62. 4,5-dihydro-
63. 2-((2,6-dichlorophenyl)amino)-2-imidazoline Hydrochloride
64. 2-imidazoline, 2-(2,6-dichloroanilino)-, Monohydrochloride
65. 2-(2,6-dichlorophenylamino)-2-imidazolin Hydrochlorid [german]
66. Benzenamine, 2,6-dichloro-n-2-imidazolidinylidene-, Hydrochloride
67. Clonidine Hydrochloride [usan:usp:ban:jan]
68. 1h-imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-, Monohydrochloride
69. Clonidinehydrochloride
70. N-(2,6-dichlorophenyl)-
71. Chembl1705
72. Clonidine Hydrochloride,(s)
73. Dsstox_cid_24670
74. Dsstox_rid_80388
75. Dsstox_gsid_44670
76. Schembl40751
77. Mls000758256
78. Mls001424222
79. Clonidine Hydrochloride, Solid
80. 2-(2,6-dichlorophenylamino)-2-imidazolin Hydrochlorid
81. Chebi:3758
82. Dtxsid8044670
83. Hy-b0409a
84. Clonidine Hydrochloride (catapres)
85. Hms1568b18
86. Hms3414h03
87. Hms3678h03
88. Pharmakon1600-01500198
89. Bcp14375
90. Clonidine Hydrochloride [mi]
91. Tox21_301552
92. Tox21_500268
93. Bdbm50020341
94. Ccg-40087
95. Clonidine Hydrochloride (jp17/usp)
96. Clonidine Hydrochloride [jan]
97. N-(2,6-dichlorophenyl)-4,5-dihydro-1h-imidazol-2-amine;hydrochloride
98. Nsc756699
99. S2458
100. Clonidine Hydrochloride [usan]
101. Akos005267207
102. Akos024458609
103. Akos028114993
104. Ccg-101051
105. Ccg-212540
106. Ccg-229466
107. Clonidine Hydrochloride [mart.]
108. Clonidine Hydrochloride [vandf]
109. Ks-1253
110. Lp00268
111. Nc00301
112. Nsc 756699
113. Clonidine Hydrochloride [usp-rs]
114. Clonidine Hydrochloride [who-dd]
115. Ncgc00093726-01
116. Ncgc00093726-02
117. Ncgc00180902-01
118. Ncgc00256172-01
119. Ncgc00260953-01
120. Ac-10306
121. Ac-29742
122. Clonidine Hydrochloride, >=98.0% (tlc)
123. Clonidine Hydrochloride [ep Impurity]
124. Clonidine Hydrochloride [orange Book]
125. D1353
126. Eu-0100268
127. Ft-0601096
128. Ft-0665123
129. Sw197681-3
130. Clonidine Hydrochloride [ep Monograph]
131. C 7897
132. Clonidine Hydrochloride [usp Monograph]
133. D00604
134. D81843
135. Clorpres Component Clonidine Hydrochloride
136. A825736
137. Clonidine Hydrochloride 100 Microg/ml In Methanol
138. Combipres Component Clonidine Hydrochloride
139. Clonidine Hydrochloride Component Of Clorpres
140. Q-200880
141. Sr-01000075246-1
142. Sr-01000075246-3
143. Sr-01000759380-5
144. Clonidine Hydrochloride (catapres) [largely Precursor]
145. Clonidine Hydrochloride Component Of Combipres
146. Q27292429
147. 2-[(2,6-dichlorophenyl)imino]imidazolidine Hydrochloride
148. Clonidine Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
149. Clonidine Hydrochloride, British Pharmacopoeia (bp) Reference Standard
150. Clonidine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
151. Clonidine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
152. 1h-imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-, Hydrochloride (1:1)
153. N-[2,6-bis(chloranyl)phenyl]-4,5-dihydro-1h-imidazol-2-amine Hydrochloride
Molecular Weight | 266.6 g/mol |
---|---|
Molecular Formula | C9H10Cl3N3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 2 |
Exact Mass | 264.994030 g/mol |
Monoisotopic Mass | 264.994030 g/mol |
Topological Polar Surface Area | 36.4 Ų |
Heavy Atom Count | 15 |
Formal Charge | 0 |
Complexity | 222 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Clonidine hydrochloride |
PubMed Health | Clonidine |
Drug Classes | Analgesic, Anesthetic Adjunct, Antihypertensive, Antimigraine, Cardiovascular Agent, Central Nervous System Agent, Diagnostic Agent, Pheochromocytoma |
Drug Label | Clonidine hydrochloride, USP is a centrally acting alpha-agonist hypotensive agent available as tablets for oral administration in three dosage strengths: 0.1 mg, 0.2 mg, and 0.3 mg. The 0.1 mg tablet is equivalent to 0.087 mg of the free base.The fo... |
Active Ingredient | Clonidine hydrochloride |
Dosage Form | Tablet, extended release; Injectable; Tablet |
Route | Injection; Oral |
Strength | 0.2mg; 1mg/10ml (0.1mg/ml); 0.3mg; 5mg/10ml (0.5mg/ml); 0.1mg |
Market Status | Prescription |
Company | Exela Pharma Scs; Anchen Pharms; Actavis Elizabeth; Fresenius Kabi Usa; Unichem; Mutual Pharm; Vintage; Alembic Pharms; Hikma Farmaceutica; Luitpold; Sun Pharm Inds; Zydus Pharms Usa; Carlsbad; Mylan; Impax Labs; Dava Pharms |
2 of 4 | |
---|---|
Drug Name | Kapvay |
Drug Label | KAPVAY (clonidine hydrochloride) extended-release is a centrally acting alpha2-adrenergic agonist available as 0.1 mg or 0.2 mg extended-release tablets for oral administration. Each 0.1 mg and 0.2 mg tablet is equivalent to 0.087 mg and 0.174 mg, re... |
Active Ingredient | Clonidine hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 0.1mg; 0.2mg |
Market Status | Prescription |
Company | Concordia Pharms |
3 of 4 | |
---|---|
Drug Name | Clonidine hydrochloride |
PubMed Health | Clonidine |
Drug Classes | Analgesic, Anesthetic Adjunct, Antihypertensive, Antimigraine, Cardiovascular Agent, Central Nervous System Agent, Diagnostic Agent, Pheochromocytoma |
Drug Label | Clonidine hydrochloride, USP is a centrally acting alpha-agonist hypotensive agent available as tablets for oral administration in three dosage strengths: 0.1 mg, 0.2 mg, and 0.3 mg. The 0.1 mg tablet is equivalent to 0.087 mg of the free base.The fo... |
Active Ingredient | Clonidine hydrochloride |
Dosage Form | Tablet, extended release; Injectable; Tablet |
Route | Injection; Oral |
Strength | 0.2mg; 1mg/10ml (0.1mg/ml); 0.3mg; 5mg/10ml (0.5mg/ml); 0.1mg |
Market Status | Prescription |
Company | Exela Pharma Scs; Anchen Pharms; Actavis Elizabeth; Fresenius Kabi Usa; Unichem; Mutual Pharm; Vintage; Alembic Pharms; Hikma Farmaceutica; Luitpold; Sun Pharm Inds; Zydus Pharms Usa; Carlsbad; Mylan; Impax Labs; Dava Pharms |
4 of 4 | |
---|---|
Drug Name | Kapvay |
Drug Label | KAPVAY (clonidine hydrochloride) extended-release is a centrally acting alpha2-adrenergic agonist available as 0.1 mg or 0.2 mg extended-release tablets for oral administration. Each 0.1 mg and 0.2 mg tablet is equivalent to 0.087 mg and 0.174 mg, re... |
Active Ingredient | Clonidine hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 0.1mg; 0.2mg |
Market Status | Prescription |
Company | Concordia Pharms |
Sedation
Adrenergic alpha-2 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Sympatholytics
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
GDUFA
DMF Review : Complete
Rev. Date : 2015-01-29
Pay. Date : 2015-01-16
DMF Number : 12964
Submission : 1998-04-27
Status : Active
Type : II
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
GDUFA
DMF Review : Complete
Rev. Date : 2015-01-29
Pay. Date : 2015-01-16
DMF Number : 4778
Submission : 1983-01-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5446
Submission : 1984-06-04
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6307
Submission : 1986-04-25
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5998
Submission : 1985-05-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4493
Submission : 1982-04-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6357
Submission : 1986-05-12
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6128
Submission : 1985-11-20
Status : Inactive
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6376
Submission : 1986-05-30
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5874
Submission : 1985-05-20
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
Certificate Number : CEP 1998-112 - Rev 04
Status : Valid
Issue Date : 2024-02-01
Type : Chemical
Substance Number : 477
Certificate Number : R1-CEP 2014-039 - Rev 01
Status : Valid
Issue Date : 2022-11-29
Type : Chemical
Substance Number : 477
Certificate Number : R1-CEP 2003-038 - Rev 00
Status : Valid
Issue Date : 2009-05-14
Type : Chemical
Substance Number : 477
Certificate Number : CEP 2022-326 - Rev 00
Status : Valid
Issue Date : 2024-07-08
Type : Chemical
Substance Number : 477
Certificate Number : R0-CEP 2022-153 - Rev 00
Status : Valid
Issue Date : 2022-11-21
Type : Chemical
Substance Number : 477
Certificate Number : CEP 2004-072 - Rev 01
Status : Valid
Issue Date : 2024-11-07
Type : Chemical
Substance Number : 477
Date of Issue : 2022-07-26
Valid Till : 2025-07-02
Written Confirmation Number : WC-0081
Address of the Firm : API Division Panelav, Tal-Halol, Dist-Panchmahal, Gujarat, India
Date of Issue : 2022-07-26
Valid Till : 2025-07-02
Written Confirmation Number : WC-0081
Address of the Firm : API Division Panelav, Tal-Halol, Dist-Panchmahal, Gujarat, India
Clonidine Hydrochloride IP/BP/EP/USP
Date of Issue : 2023-03-21
Valid Till : 2026-03-20
Written Confirmation Number : WC-0552
Address of the Firm : Plot No. D-2/CH/41A, GIDC Industrial Estate, Dahej Il, Bharuch-392140, Gujarat, ...
Clonidine Hydrochloride Ph.Eur
Date of Issue : 2022-06-30
Valid Till : 2025-07-28
Written Confirmation Number : WC-0063
Address of the Firm : Plot No. 99, MIDC Area - Dhatav Roha, Dist. Raigad, Roha, Raigad-402116, Maharas...
Date of Issue : 2022-06-17
Valid Till : 2025-07-21
Written Confirmation Number : WC-0062
Address of the Firm : Plot No. 197, Sector - I, Pithampur, Dist. Dhar, Madhya Pradesh
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
NDC Package Code : 51014-7543
Start Marketing Date : 2009-08-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
NDC Package Code : 51014-7944
Start Marketing Date : 1998-04-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
NDC Package Code : 51014-7544
Start Marketing Date : 2009-08-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 42413-0053
Start Marketing Date : 2018-03-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51552-0480
Start Marketing Date : 1998-04-01
End Marketing Date : 2026-03-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 62991-1422
Start Marketing Date : 2010-10-25
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 51927-2379
Start Marketing Date : 2013-06-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 82393-209
Start Marketing Date : 2022-04-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 12660-0002
Start Marketing Date : 1979-02-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49452-2147
Start Marketing Date : 1993-10-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
About the Company : Since its inception in 2003, Seqens has evolved into a global leader in pharmaceutical solutions and specialty ingredients. With a strong focus on customer support, Seqens assists ...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...
About the Company : Enaltec Labs was established in 2006 by a group of young & experienced professionals with the specific objective to develop & produce complex, small volume, technology driven produ...
About the Company : Public health is always an imperative that implies immense responsibility, not a mere re-adjustable option. As a company operating under world’s second largest industry of Pharma...
About the Company : Osmopharm S.A. is a GMP approved pharmaceutical company located in Switzerland and specialized in development and production of modified release solid oral form drugs under contrac...
About the Company : Promoted by a pioneer of the Indian pharmaceuticals business, Mr. Amrut Mody, Unichem Laboratories has grown to become one of India’s most respected pharmaceutical companies. It ...
About the Company : Our work in the distribution sector starts and ends with the quality of human relations; first and foremost, it is trust that we want to build with you. The connections we build ar...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
FDA has approved ONYDA™ XR (clonidine hydrochloride), a once-a-day extended-release oral suspension for the treatment of ADHD in pediatric patients six years and older.
Lead Product(s): Clonidine
Therapeutic Area: Psychiatry/Psychology Brand Name: Onyda
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 29, 2024
Lead Product(s) : Clonidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris Pharma Gets FDA Approval for ONYDA XR, First Liquid ADHD Medication
Details : FDA has approved ONYDA™ XR (clonidine hydrochloride), a once-a-day extended-release oral suspension for the treatment of ADHD in pediatric patients six years and older.
Product Name : Onyda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 29, 2024
Details:
JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate osteoarthritis pain.
Lead Product(s): Clonidine,Hyaluronic Acid
Therapeutic Area: Musculoskeletal Brand Name: JTA-004
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 17, 2023
Lead Product(s) : Clonidine,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioSenic Reacquires Global IP Rights and Provides Update On JTA-004 Development
Details : JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate os...
Product Name : JTA-004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2023
Details:
Validive® (clonidine hydrochloride) is a novel mucobuccal tablet formulation, indiacted for oropharyngeal cancer. It agonizes the alpha-2 adrenergic receptor on macrophages, decreasing the release of the destructive cytokines that are produced in response to radiotherapy.
Lead Product(s): Clonidine
Therapeutic Area: Gastroenterology Brand Name: Validive
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 27, 2023
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Validive® (clonidine hydrochloride) is a novel mucobuccal tablet formulation, indiacted for oropharyngeal cancer. It agonizes the alpha-2 adrenergic receptor on macrophages, decreasing the release of the destructive cytokines that are produced in respon...
Product Name : Validive
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2023
Details:
JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate osteoarthritis pain.
Lead Product(s): Clonidine
Therapeutic Area: Musculoskeletal Brand Name: JTA-004
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 16, 2023
Lead Product(s) : Clonidine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate os...
Product Name : JTA-004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2023
Details:
Validive® (clonidine hydrochloride) is a novel mucobuccal tablet (MBT) formulation of clonidine. The mucobuccal tablet provides for prolonged local delivery of clonidine to the regions of oral mucosal radiation damage in oropharyngeal cancer (OPC) patients.
Lead Product(s): Clonidine
Therapeutic Area: Gastroenterology Brand Name: Validive
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 27, 2022
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
Details : Validive® (clonidine hydrochloride) is a novel mucobuccal tablet (MBT) formulation of clonidine. The mucobuccal tablet provides for prolonged local delivery of clonidine to the regions of oral mucosal radiation damage in oropharyngeal cancer (OPC) patie...
Product Name : Validive
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2022
Details:
Validive® (clonidine HCl MBT) is a novel mucobuccal tablet (MBT) formulation of clonidine. A completed double-blind, randomized, placebo-controlled Phase 2 clinical trial showed reduced incidence and duration of SOM and improvement of oral mucositis-related symptoms.
Lead Product(s): Clonidine
Therapeutic Area: Gastroenterology Brand Name: Validive
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 10, 2022
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Validive® (clonidine HCl MBT) is a novel mucobuccal tablet (MBT) formulation of clonidine. A completed double-blind, randomized, placebo-controlled Phase 2 clinical trial showed reduced incidence and duration of SOM and improvement of oral mucositis-rel...
Product Name : Validive
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2022
Details:
The launch of Nexiclon XR, the only once-daily clonidine extended-release tablets is based on Tris's LiquiXR drug delivery technology, which has led to the development of multiple first-in-category products indicated for treatment of hypertension.
Lead Product(s): Clonidine
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Nexiclon
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 03, 2022
Lead Product(s) : Clonidine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Athena Bioscience Announces Launch of Nexiclon™ XR, the Only Once-Daily Clonidine Extended-Relea...
Details : The launch of Nexiclon XR, the only once-daily clonidine extended-release tablets is based on Tris's LiquiXR drug delivery technology, which has led to the development of multiple first-in-category products indicated for treatment of hypertension.
Product Name : Nexiclon
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2022
Details:
This partnership aligns perfectly with Sabal’s mission to support commercial launch for two products, Nexiclon™ XR and Fibricor®, by helping them deliver their products to physicians and patients who need them.
Lead Product(s): Clonidine
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Nexiclon XR
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Athena Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 22, 2022
Lead Product(s) : Clonidine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Athena Bioscience
Deal Size : Undisclosed
Deal Type : Agreement
Details : This partnership aligns perfectly with Sabal’s mission to support commercial launch for two products, Nexiclon™ XR and Fibricor®, by helping them deliver their products to physicians and patients who need them.
Product Name : Nexiclon XR
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 22, 2022
Details:
The trial, which began earlier this year in the US, is evaluating Validive® (clonidine HCl MBT) to prevent the onset of severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients treated with chemoradiotherapy.
Lead Product(s): Clonidine
Therapeutic Area: Gastroenterology Brand Name: Validive
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 13, 2021
Lead Product(s) : Clonidine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe
Details : The trial, which began earlier this year in the US, is evaluating Validive® (clonidine HCl MBT) to prevent the onset of severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients treated with chemoradiotherapy.
Product Name : Validive
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2021
Details:
The JTA-004 Phase III study is a controlled, randomized, double-blind trial. It is evaluating the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee up to 12 months, compared to placebo or Hylan G-F 20.
Lead Product(s): Clonidine
Therapeutic Area: Musculoskeletal Brand Name: JTA-004
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 19, 2021
Lead Product(s) : Clonidine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bone Therapeutics Provides Update on the Progress of Clinical Studies
Details : The JTA-004 Phase III study is a controlled, randomized, double-blind trial. It is evaluating the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee up to 12 months, compared to placebo or Hylan G-F 20.
Product Name : JTA-004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2021
RLD : No
TE Code :
Brand Name : NEXICLON XR
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 0.17MG BASE
Approval Date : 2009-12-03
Application Number : 22500
RX/OTC/DISCN : RX
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : NEXICLON XR
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 0.26MG BASE
Approval Date : 2009-12-03
Application Number : 22500
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : CLONIDINE
Dosage Form : SYSTEM;TRANSDERMAL
Dosage Strength : 0.1MG/24HR
Approval Date : 2010-08-20
Application Number : 79090
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : CLONIDINE
Dosage Form : SYSTEM;TRANSDERMAL
Dosage Strength : 0.2MG/24HR
Approval Date : 2010-08-20
Application Number : 79090
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : CLONIDINE
Dosage Form : SYSTEM;TRANSDERMAL
Dosage Strength : 0.3MG/24HR
Approval Date : 2010-08-20
Application Number : 79090
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : CLONIDINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 0.1MG
Approval Date : 1986-12-16
Application Number : 70974
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : CLONIDINE HYDROCHLORIDE
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 5MG/10ML (0.5MG/ML)
Approval Date : 2009-10-08
Application Number : 91104
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : CLONIDINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 0.1MG
Approval Date : 1988-04-05
Application Number : 71785
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : CLONIDINE HYDROCHLORIDE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 0.2MG
Approval Date : 2014-04-02
Application Number : 202983
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE
Brand Name : CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE
Dosage Form : TABLET;ORAL
Dosage Strength : 15MG;0.1MG
Approval Date : 1987-12-16
Application Number : 71179
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
12
PharmaCompass offers a list of Clonidine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Clonidine manufacturer or Clonidine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Clonidine manufacturer or Clonidine supplier.
PharmaCompass also assists you with knowing the Clonidine API Price utilized in the formulation of products. Clonidine API Price is not always fixed or binding as the Clonidine Price is obtained through a variety of data sources. The Clonidine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Chlophazolin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Chlophazolin, including repackagers and relabelers. The FDA regulates Chlophazolin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Chlophazolin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Chlophazolin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Chlophazolin supplier is an individual or a company that provides Chlophazolin active pharmaceutical ingredient (API) or Chlophazolin finished formulations upon request. The Chlophazolin suppliers may include Chlophazolin API manufacturers, exporters, distributors and traders.
click here to find a list of Chlophazolin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Chlophazolin DMF (Drug Master File) is a document detailing the whole manufacturing process of Chlophazolin active pharmaceutical ingredient (API) in detail. Different forms of Chlophazolin DMFs exist exist since differing nations have different regulations, such as Chlophazolin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Chlophazolin DMF submitted to regulatory agencies in the US is known as a USDMF. Chlophazolin USDMF includes data on Chlophazolin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Chlophazolin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Chlophazolin suppliers with USDMF on PharmaCompass.
A Chlophazolin CEP of the European Pharmacopoeia monograph is often referred to as a Chlophazolin Certificate of Suitability (COS). The purpose of a Chlophazolin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Chlophazolin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Chlophazolin to their clients by showing that a Chlophazolin CEP has been issued for it. The manufacturer submits a Chlophazolin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Chlophazolin CEP holder for the record. Additionally, the data presented in the Chlophazolin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Chlophazolin DMF.
A Chlophazolin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Chlophazolin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Chlophazolin suppliers with CEP (COS) on PharmaCompass.
A Chlophazolin written confirmation (Chlophazolin WC) is an official document issued by a regulatory agency to a Chlophazolin manufacturer, verifying that the manufacturing facility of a Chlophazolin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Chlophazolin APIs or Chlophazolin finished pharmaceutical products to another nation, regulatory agencies frequently require a Chlophazolin WC (written confirmation) as part of the regulatory process.
click here to find a list of Chlophazolin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Chlophazolin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Chlophazolin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Chlophazolin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Chlophazolin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Chlophazolin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Chlophazolin suppliers with NDC on PharmaCompass.
Chlophazolin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Chlophazolin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Chlophazolin GMP manufacturer or Chlophazolin GMP API supplier for your needs.
A Chlophazolin CoA (Certificate of Analysis) is a formal document that attests to Chlophazolin's compliance with Chlophazolin specifications and serves as a tool for batch-level quality control.
Chlophazolin CoA mostly includes findings from lab analyses of a specific batch. For each Chlophazolin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Chlophazolin may be tested according to a variety of international standards, such as European Pharmacopoeia (Chlophazolin EP), Chlophazolin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Chlophazolin USP).